PBM therapy improves color vision in congenital CVD.

Green CVD shows greatest benefit from non-invasive PBM.

Randomized trials confirm PBM's superior efficacy over controls across multiple metrics including FM-100 scores.

Congenital color vision deficiency (CVD) is a prevalent ophthalmic condition for which effective therapeutic interventions remain limited. This study evaluated the efficacy of photobiomodulation (PBM) therapy in individuals with congenital CVD.

A randomized, single-blind, controlled clinical trial was conducted involving 80 participants diagnosed with red-green CVD. Participants were randomly assigned to either a PBM treatment group or a control group. Color vision performance was assessed at baseline, and after 1, 2, and 4 weeks of intervention. Statistical analyses were conducted using the Kruskal-Wallis test with Dunn’s post hoc test for multiple comparisons.

Color vision recognition ability demonstrated a statistically significant improvement in the PBM treatment group compared to the control group across various parameters (p < 0.05).

Non-invasive PBM therapy significantly enhances color vision in individuals with congenital CVD, with particularly notable improvements observed in those with green CVD.

Color vision test

Congenital color vision deficiency

Photobiomodulation

Randomized controlled trial

Color vision deficiency

Farnsworth Munsell 100

© 2025 The Authors. Published by Elsevier B.V.